Last reviewed · How we verify
SARS-CoV-2 convalescent plasma treatment — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
SARS-CoV-2 convalescent plasma treatment (SARS-CoV-2 convalescent plasma treatment) — Fundación Santa Fe de Bogota.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SARS-CoV-2 convalescent plasma treatment TARGET | SARS-CoV-2 convalescent plasma treatment | Fundación Santa Fe de Bogota | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SARS-CoV-2 convalescent plasma treatment CI watch — RSS
- SARS-CoV-2 convalescent plasma treatment CI watch — Atom
- SARS-CoV-2 convalescent plasma treatment CI watch — JSON
- SARS-CoV-2 convalescent plasma treatment alone — RSS
Cite this brief
Drug Landscape (2026). SARS-CoV-2 convalescent plasma treatment — Competitive Intelligence Brief. https://druglandscape.com/ci/sars-cov-2-convalescent-plasma-treatment. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab